Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

311
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
311

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Where You Live Shapes Diabetes Risk: Multilevel Determinants of Type 2 Diabetes in the East South Central United States.

Journal of racial and ethnic health disparities·2026
Same author

Systematic Design of Molecularly Imprinted Polymers for Triclosan Using Design of Experiments and Molecular Dynamics Simulations.

Polymers·2026
Same author

Cost-Utility Analysis Alongside the GORTEC 2014-01 TPExtreme trial - Author Response to Letter to the Editor.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same author

The Assessment of the Effect of Nano Propolis Against Melanoma Cell Line, and Its Radio Sensitization Effect.

Food science & nutrition·2026
Same author

Epidemiology and Treatment Patterns of Stage III Resectable Melanoma Treated with Adjuvant Therapy: A Real-World Study Using the SNDS Database in France.

Dermatology and therapy·2026
Same author

Development and internal validation of a clinical risk prediction model for pancreatic ductal adenocarcinoma in the UK Biobank.

European journal of cancer (Oxford, England : 1990)·2026

Related Experiment Video

Updated: May 16, 2025

Culture of Bladder Cancer Organoids as Precision Medicine Tools
08:39

Culture of Bladder Cancer Organoids as Precision Medicine Tools

Published on: December 28, 2021

4.5K

Characteristics, management and survival outcomes in patients with muscle-invasive bladder cancer at high risk of

Aldéric Fraslin1,2, Florian Colrat3, Maryam Karimi1,2

  • 1Bureau Biostatistique et Epidémiologie, Gustave Roussy, Université Paris-Saclay, Villejuif, France.

BMC Urology
|May 12, 2025
PubMed
Summary

Patients with muscle-invasive bladder cancer (MIBC) at high risk of recurrence (MIBC-HR) undergoing radical cystectomy (RC) have a poor prognosis. This study highlights the need for new treatments, like immunotherapies, to improve survival for MIBC-HR patients.

Keywords:
Adjuvant chemotherapyBladder cancerMuscle-invasive urothelial carcinomaProspective cohortRadical cystectomySurvival

More Related Videos

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.2K
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.4K

Related Experiment Videos

Last Updated: May 16, 2025

Culture of Bladder Cancer Organoids as Precision Medicine Tools
08:39

Culture of Bladder Cancer Organoids as Precision Medicine Tools

Published on: December 28, 2021

4.5K
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.2K
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.4K

Area of Science:

  • Urology
  • Oncology
  • Clinical Research

Background:

  • Muscle-invasive bladder cancer (MIBC) poses a significant challenge, particularly in high-risk (HR) patients.
  • Radical cystectomy (RC) is a primary treatment, but outcomes for MIBC-HR patients remain suboptimal.

Purpose of the Study:

  • To characterize patients with MIBC at high risk of recurrence (MIBC-HR) undergoing RC in France.
  • To evaluate disease-free survival (DFS) and overall survival (OS) in MIBC-HR patients, including a subgroup managed with active surveillance only (ASO).

Main Methods:

  • Analysis of a prospective cohort (COBLAnCE) of MIBC patients aged ≥18 years who underwent RC between October 2012 and June 2018.
  • Patients classified as MIBC-HR based on TNM staging; metastatic disease excluded.
  • Survival outcomes estimated using the Kaplan-Meier method.

Main Results:

  • 256 MIBC-HR patients were analyzed; median age 68.5 years, 79.7% male, 88.3% with pT3a or higher stage.
  • Median DFS was 1.30 years and median OS was 2.31 years for the overall MIBC-HR cohort.
  • Five-year DFS was 27.4% and five-year OS was 33.2% in the MIBC-HR cohort.

Conclusions:

  • Radical cystectomy for MIBC-HR patients yields challenging prognoses, irrespective of adjuvant chemotherapy.
  • Current treatments offer limited efficacy, underscoring the need for novel therapeutic strategies.
  • Emerging treatments like immunotherapies hold promise for improving survival in MIBC-HR.